ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$224.53
arrow_upward
+0.05%(+0.12) 1D
$224.53
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 8, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
$222.03
High
$225.90
Low
$218.39
Mkt. cap
30.04B
Avg. vol.
1.48M
Volume
1.77M
P/E ratio
38.21
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
Open
$222.03
High
$225.90
Low
$218.39
Mkt. cap
30.04B
Avg. vol.
1.48M
Volume
1.77M
P/E ratio
38.21
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
News stories
From web sources and news partners
Zacks
·
10 hours ago
Here's Why You Should Add LPCN Stock to Your Portfolio Now
GuruFocus
·
10 hours ago
ALNY Maintained by RBC Capital -- Price Target Lowered to $345
Zacks
·
10 hours ago
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
Simply Wall Street
·
13 hours ago
Alnylam Pharmaceuticals (ALNY) Is Under Securities Fraud Investigation
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.